Kailera closes $600 million Series B led by Bain Capital, bringing total funding to over $1 billion

Kailera Therapeutics/Ribupatide (KAI-9531)

Kailera announced a $600 million Series B financing led by Bain Capital Private Equity, bringing total capital raised to over $1 billion. Funds support continued Phase 3 development of ribupatide, manufacturing scale-up, and advancement of an oral formulation.

• Bain Capital led the round; existing investors also participated.
• Series B funding enables completion of Phase 3 trials and preparation for regulatory submissions.
• Oral tablet development is advancing in parallel with the injectable program.